$21.8 M

FCSC Mkt cap, 20-Jul-2018
Fibrocell Science Net income (Q1, 2018)-2.9 M
Fibrocell Science EBIT (Q1, 2018)-3 M
Fibrocell Science Cash, 31-Mar-201812.2 M

Fibrocell Science Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

200 k180 k492 k355 k

Revenue growth, %

(10%)173%(28%)

Cost of goods sold

722 k697 k

Gross profit

(230 k)(342 k)

Gross profit Margin, %

(47%)(96%)

R&D expense

6.5 m

General and administrative expense

6.7 m

Operating expense total

13.3 m

EBIT

(37.4 m)(26.5 m)(19 m)

EBIT margin, %

(7603%)(7459%)

Interest expense

228 k828 k

Interest income

8 k

Pre tax profit

(34.5 m)(15.3 m)(16.2 m)

Income tax expense

Net Income

(30.6 m)(25.7 m)(34.5 m)(15.3 m)(16.2 m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

194 k137 k79 k16 k87 k215 k

Cost of goods sold

1.9 m793 k547 k512 k147 k162 k204 k18 k392 k287 k

Gross profit

47 k(25 k)(125 k)(2 k)(305 k)(72 k)

Gross profit Margin, %

24%(18%)(158%)(12%)(351%)(33%)

R&D expense

8.4 m7.4 m1.6 m

General and administrative expense

2.9 m2.8 m1.6 m

Operating expense total

11.3 m10.3 m3.3 m

EBIT

(13.1 m)(11 m)(6.6 m)(6.2 m)(6.9 m)(7.4 m)(6.8 m)(6.7 m)(10.3 m)(5 m)(4.5 m)(5 m)(3 m)

EBIT margin, %

(3538%)(5372%)(8637%)(41675%)(11861%)(2333%)

Interest expense

46 k183 k185 k190 k

Interest income

1 k1 k2 k2 k1 k1 k4 k4 k12 k

Pre tax profit

(12.9 m)(14 m)(2.3 m)(6 m)(8.5 m)(6.8 m)(1.5 m)(1.4 m)(8.1 m)(2.3 m)(5 m)(14 m)(2.9 m)

Income tax expense

Net Income

(12.9 m)(14 m)(2.3 m)(6 m)(8.5 m)(6.8 m)(1.5 m)(1.4 m)(8.1 m)(2.3 m)(5 m)(14 m)(2.9 m)

Fibrocell Science Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

60 m37.5 m29.3 m17.5 m17.4 m

Accounts Receivable

Inventories

1.2 m1.3 m1.2 m

Current Assets

61.9 m39.3 m31 m18 m17.9 m

PP&E

1.7 m1.6 m1.6 m1.5 m

Total Assets

69 m45.6 m36.7 m19.6 m19.4 m

Accounts Payable

3 m1.1 m499 k440 k862 k

Short-term debt

Current Liabilities

3.6 m3.5 m15.4 m3 m4.4 m

Long-term debt

Total Liabilities

11.7 m10.4 m

Additional Paid-in Capital

167.3 m143.1 m161.3 m170.4 m187.8 m

Retained Earnings

(102.7 m)(112.7 m)(147.2 m)(162.6 m)(178.8 m)

Total Equity

64.7 m14.2 m7.9 m9 m

Financial Leverage

1.1 x2.6 x2.5 x2.2 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

16.9 m54 m49.5 m44.2 m33.3 m26.9 m36.9 m13.1 m8.2 m21.3 m20.6 m15.9 m12.2 m

Inventories

574 k506 k476 k610 k544 k484 k566 k475 k109 k

Current Assets

19.2 m55.5 m50.7 m45.3 m34.9 m28.1 m38 m14.6 m8.9 m21.7 m21.1 m16.4 m12.7 m

Total Assets

26.3 m62.4 m57.4 m51.9 m41.2 m34.1 m43.9 m20.2 m10.5 m23.2 m22.7 m18 m14.1 m

Accounts Payable

1.2 m903 k1.4 m1.1 m1.9 m2 m2.6 m893 k553 k361 k566 k658 k508 k

Current Liabilities

2.6 m2.4 m3.2 m3.6 m6 m5.2 m5.3 m3.4 m3.1 m2.5 m3 m3.4 m1.9 m

Total Liabilities

3.3 m21.3 m18.1 m18.3 m18.9 m17.7 m12.6 m6.9 m4.7 m12.2 m12.2 m21.4 m7.9 m

Additional Paid-in Capital

120 m142.2 m142.6 m142.9 m143.5 m144.4 m160.8 m162 m162.6 m170.1 m178 m178.1 m187.9 m

Retained Earnings

(97.1 m)(101.1 m)(103.3 m)(109.3 m)(121.2 m)(128 m)(129.5 m)(148.7 m)(156.8 m)(159.1 m)(167.6 m)(181.6 m)(181.7 m)

Total Equity

23 m41.1 m39.3 m33.5 m16.4 m31.4 m13.3 m5.8 m11 m10.5 m(3.4 m)6.3 m

Financial Leverage

1.1 x1.5 x1.5 x1.5 x2.1 x1.4 x1.5 x1.8 x2.1 x2.2 x-5.2 x2.3 x

Fibrocell Science Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(30.6 m)(25.7 m)(34.5 m)(15.3 m)(16.2 m)

Depreciation and Amortization

863 k883 k767 k564 k384 k

Accounts Receivable

54 k12 k9 k12 k

Inventories

(120 k)26 k35 k126 k

Accounts Payable

2 m(1.8 m)(114 k)(139 k)69 k

Cash From Operating Activities

(20.1 m)(22.3 m)(24.1 m)(29.4 m)(17 m)

Purchases of PP&E

(360 k)(242 k)(271 k)(253 k)(433 k)

Cash From Investing Activities

(360 k)(242 k)(245 k)(252 k)(433 k)

Dividends Paid

Cash From Financing Activities

49.1 m16.1 m17.9 m17.4 m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(25 m)(14 m)(16.3 m)(22.3 m)(8.5 m)(15.3 m)(1.5 m)(1.4 m)(8.1 m)(2.3 m)(5 m)(19 m)(2.9 m)

Depreciation and Amortization

693 k222 k452 k673 k140 k346 k91 k184 k

Accounts Receivable

23 k(35 k)(2 k)11 k1 k2 k

Inventories

(97 k)91 k121 k(13 k)27 k87 k566 k475 k

Accounts Payable

248 k(2.1 m)(1.6 m)(1.9 m)774 k833 k2.6 m893 k553 k361 k(55 k)192 k23 k

Cash From Operating Activities

(16 m)(6 m)(10.3 m)(15.5 m)(4.2 m)(10.8 m)(4.8 m)(9 m)(4.8 m)

Purchases of PP&E

(162 k)(79 k)(211 k)(307 k)(108 k)(111 k)(87 k)(243 k)(35 k)

Cash From Investing Activities

(162 k)(211 k)(307 k)(108 k)(111 k)(87 k)(243 k)(35 k)

Cash From Financing Activities

1.7 m152 k253 k7.9 m7.6 m(420 k)

Fibrocell Science Ratios

USDY, 2018

Financial Leverage

2.3 x
Report incorrect company information